Strides Pharma Science Ltd (BOM:532531)

₹ 1634.5 39.35 (2.47%) Market Cap: 150.72 Bil Enterprise Value: 170.45 Bil PE Ratio: 64.92 PB Ratio: 6.62 GF Score: 68/100

Q2 2025 Strides Pharma Science Ltd Earnings Call Transcript
Oct 24, 2024

₹1534.65 (-1.54%)

Earnings
Q1 2025 Strides Pharma Science Ltd Earnings Call Transcript
Jul 29, 2024

₹1033.75 (+1.15%)

Earnings
Q4 2024 Strides Pharma Science Ltd Earnings Call Transcript
May 22, 2024

₹900.05 (+6.37%)

Earnings
Q3 2024 Strides Pharma Science Ltd Earnings Call Transcript
Jan 30, 2024

₹700.1 (+2.43%)

Earnings
Q2 2024 Strides Pharma Science Ltd Earnings Call Transcript
Oct 30, 2023

₹488.9 (-1.87%)

Earnings
Strides Pharma Science Ltd to Consider to Combine CDMO Interests Call Transcript
Sep 25, 2023
Q1 2024 Strides Pharma Science Ltd Earnings Call Transcript
Aug 02, 2023

₹446.3 (-7.06%)

Earnings
Q4 2023 Strides Pharma Science Ltd Earnings Call Transcript
May 25, 2023

₹362.85 (-3.91%)

Earnings
Q3 2023 Strides Pharma Science Ltd Earnings Call Transcript
Jan 24, 2023

₹318.5 (-5.39%)

Earnings
Q2 2023 Strides Pharma Science Ltd Earnings Call Transcript
Nov 14, 2022

₹345.05 (+8.34%)

Earnings
Q1 2023 Strides Pharma Science Ltd Earnings Call Transcript
Jul 29, 2022

₹331.35 (-0.85%)

Earnings
Q4 2022 Strides Pharma Science Ltd Earnings Call Transcript
May 25, 2022

₹306.3 (+1.19%)

Earnings
Q3 2022 Strides Pharma Science Ltd Earnings Call Transcript
Feb 10, 2022

₹390.25 (-1.23%)

Earnings
Q2 2022 Strides Pharma Science Ltd Earnings Call Transcript
Nov 10, 2021

₹504.1 (-8.52%)

Earnings
Q1 2022 Strides Pharma Science Ltd Earnings Call Transcript
Aug 06, 2021

₹732.85 (-6.28%)

Earnings
Q4 2021 Strides Pharma Science Ltd Earnings Call Transcript
May 27, 2021

₹807.35 (-0.65%)

Earnings
Q3 2021 Strides Pharma Science Ltd Earnings Call Transcript
Feb 04, 2021

₹886.8 (-1.05%)

Earnings
Q2 2021 Strides Pharma Science Ltd Earnings Call Transcript
Oct 29, 2020

₹672.5 (-10.24%)

Earnings
Q1 2021 Strides Pharma Science Ltd Earnings Call Transcript
Aug 05, 2020

₹534.5 (+14.22%)

Earnings
Q4 2020 Strides Pharma Science Ltd Earnings Call Transcript
May 21, 2020

₹421.3 (+0.06%)

Earnings
Q3 2020 Strides Pharma Science Ltd Earnings Call Transcript
Jan 30, 2020

₹468.6 (+4.86%)

Earnings
Q2 2020 Strides Pharma Science Ltd Earnings Call Transcript
Oct 25, 2019

₹372.8 (+8.23%)

Earnings
Q1 2020 Strides Pharma Science Ltd Earnings Call Transcript
Jul 29, 2019

₹352.35 (-0.27%)

Earnings
Q4 2019 Strides Pharma Science Ltd Earnings Call Transcript
May 10, 2019

₹485.7 (+0.37%)

Earnings

Q2 2024 Strides Pharma Science Ltd Earnings Call Transcript

Oct 30, 2023 / 10:30AM GMT

Release Date Price: ₹488.9 (-1.87%)

Transcript

Operator

Ladies and gentlemen, good day, and welcome to the Strides Pharma Science Limited Q2 FY '24 Earnings Conference Call. As a reminder, all participant lines will be in the listen only mode. There will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions). Please note that this conference is being recorded. I now hand the conference over to Abhishek. Thank you, and over to you, sir.

Abhishek Singhal

Thanks. A very good afternoon, and thank you for joining us today for Strides earnings call for the second quarter ended financial year 2024. Today, we have with us Arun, Founder, Executive Chairperson and Managing Director; and Badree, Executive Director, Finance and Group CFO, to share the highlights of the business and financials for the quarter.

I hope you've gone through our results release and the quarterly investor presentation, which have been uploaded on our website as well as the stock exchange website. The transcript for this call will be available in a week's time on the company's website. Please note that

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.